Epirubicin and Cyclophosphamide Followed By Docetaxel and Trastuzumab in Treating Women With HER2-Positive Stage III or Stage IV Breast Cancer
Neoadjuvant Epirubicin/Cyclophosphamide Followed by Docetaxel Combined With Trastuzumab for the Patients With HER-Positive Advanced Breast Cancer
Sponsor: Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
A PHASE2 clinical study on Breast Cancer, this trial is completed. The trial is conducted by Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan and has accumulated 7 data snapshots since 2006. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
▶ Show 2 earlier versions
-
May 2018 — Jun 2018 [monthly]
Completed PHASE2
-
Jan 2017 — May 2018 [monthly]
Completed PHASE2
First recorded
Jan 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
For direct contact, visit the study record on ClinicalTrials.gov .